Advertisement

Clinical Rheumatology

, Volume 37, Issue 4, pp 935–941 | Cite as

Population-based study suggests an increased risk of Alzheimer’sdisease in Sjögren’s syndrome

  • Po-Chou Liliang
  • Cheng-Loong Liang
  • Kang Lu
  • San-Nan Yang
  • Meng-Tsang Hsieh
  • Yi-Cheng Tai
  • Kuo-Wei Wang
Open Access
Original Article

Abstract

This population-based study was designed to estimate and compare the risk of Alzheimer’s disease (AD) between patients with primary Sjögren’s syndrome (SS) and non-SS patients during a 10-year follow-up period. This is a retrospective cohort study. Data were obtained from the Taiwan’s National Health Insurance Research Database. We identified 4463 primary SS patients and 22,315 non-SS patients; patients were matched by sex, age, and the year of index use of health care. Each patient was studied to identify the subsequent manifestation of AD. Cox proportional hazard regression was used to study the subsequent manifestation of AD, and Kaplan-Meier survival curves were used to compare survival probability. During the 10-year follow-up period, 7 primary SS and 13 non-SS patients developed AD. During the 10-year follow-up period, the risk of AD was 2.68-fold higher in the primary SS cohort with an overall adjusted hazard ratio (HR) of 2.69 (95% CI 1.07–6.76), after adjusting for demographics and comorbidities. Within the 10-year period, patients with primary SS showed a 2.69-fold increased risk of developing AD. This risk increases with time, and the relative risk of AD is higher in older patients with primary SS.

Keywords

Alzheimer’s disease Epidemiology Sjögren’s syndrome 

Introduction

Sjögren’s syndrome (SS) is a relatively common systemic autoimmune rheumatic disease, in which lymphocytic infiltration of salivary and lacrimal glands leads to immune-mediated secretory dysfunction. The resulting dryness of the mouth and eyes is termed “sicca syndrome.” SS is referred to as “primary” in patients who do not have an additional systemic rheumatic disease, and “secondary” when immune-mediated sicca syndrome coexists in patients with systemic lupus erythematosus (SLE), scleroderma, rheumatoid arthritis (RA), or other autoimmune rheumatic diseases [1]. Systemic involvement (extraglandular manifestations) is common and often results in potentially life-threatening complications, such as lymphoma [2, 3]. Neuropsychiatric complications, including headache, cognitive dysfunction, and mood disorders, are reported in approximately 20% of SS patients [4, 5].

Recently, an association was noted between neuropsychiatric symptoms and autoimmune diseases [4]. Previous studies indicate that inflammatory mechanisms may play an important role in increasing the risk of cognitive impairment and stroke [4, 5, 6, 7]. Most of those studies focused on rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) or described an increased risk of cardiovascular disease and autoimmune dementia [6, 7, 8, 9, 10, 11, 12, 13].

This nationwide, population-based study was designed to estimate and compare the risk of Alzheimer’s disease (AD) between primary SS patients and non-SS patients during a 10-year period that followed primary SS diagnosis. We were interested in determining whether medical comorbidities or primary SS might explain such an association.

Methods

Database/standard protocol approvals, registrations, and patient consents

This study was a retrospective cohort study. The study cohort included one primary SS patient group and control group without SS but with similar comorbidities. The patients and controls used in our study were selected from Taiwan’s National Health Insurance Research Database (NHIRD) [14]. NHIRD was obtained from the National Health Research Institutes (NHRI), which is maintained by the Bureau of National Health Insurance, Taiwan. NHIRD contains non-identifying secondary data that scientists can access for research purposes. Details on database generation, monitoring, and maintenance are published online by the Taiwan National Health Research Institutes (http://nhird.nhri.org.tw/). This study was exempted from full review by the institutional review board.

Study sample

SS patients were defined as those with catastrophic illness registration cards and who met the criteria defined by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), code (710.2 for Sjögren’s syndrome). These diagnoses had to occur between 2000 and 2005 [6]. In Taiwan, SS patients can apply for catastrophic illness registration cards from the Bureau of National Health Insurance. Individuals can qualify for catastrophic illness registration cards for SS if their clinical manifestations and laboratory data meet the criteria established by specialists in rheumatology according to the criteria proposed by the American-European Consensus Group [15] and were reviewed by rheumatologists commissioned by the NHI. Individuals with these certificates do not need to make co-payments when seeking health care for SS. Thus, the catastrophic illness patient data are highly accurate and reliable. We excluded secondary SS patients from these SS patients in this study.

In order to observe the risk of developing AD in primary SS patients, subjects who were diagnosed with AD (ICD-9-CM codes 331.0) prior to SS diagnosis were excluded from the study. A total of 4463 patients that were newly diagnosed with primary SS between 2000 and 2005 were selected for the study.

A comparison cohort was randomly selected from the patient records remaining in the NHIRD. We randomly selected five comparison subjects for each identified primary SS case. We randomly selected 22,315 individuals that were matched in terms of sex, age, similar comorbidities, and the index date for the year health care services provided. The selected comorbidities included diabetes (ICD-9 code: 250.00–250.93), hyperlipidemia (ICD-9 code: 270), hypertension (ICD-9 code: 401–405), coronary artery disease (CAD) (ICD-9-CM codes: 410–414 or 429.2), heart failure (HF) (ICD-9-CM code: 428), atrial fibrillation (AF) (ICD-9-CM code: 427.31), and stroke (ICD-9-CM codes: 430–438)].

Statistical analysis

The primary goal of this study was to determine whether a primary SS patient had received ambulatory care visits or undergone hospitalizations for AD. We used Pearson’s χ 2 tests to compare differences between patients with and without SS in terms of demographic characteristics (i.e., residence location—northern, central, eastern, or southern Taiwan) and selected comorbidities [diabetes (ICD-9 code: 250.00–250.93), hyperlipidemia (ICD-9 code: 270), hypertension (ICD-9 code: 401–405), coronary artery disease (CAD) (ICD-9-CM codes: 410–414 or 429.2), heart failure (HF) (ICD-9-CM code: 428), atrial fibrillation (AF) (ICD-9-CM code: 427.31), and stroke (ICD-9-CM codes: 430–438)] at baseline [16, 17]. The baseline comorbidities were identified for subjects in both cohorts in the inpatient setting 1 year preceding the index dates.

Both the unadjusted and adjusted HRs for the analyses were obtained by evaluating the association between primary SS and AD during the 10-year follow-up period, after adjusting for demographic characteristics and selected comorbidities. The 10-year AD-free survival rates were estimated using the Kaplan–Meier method, which uses the log-rank test to examine differences between cohorts in dementia-free survival rates. Stratified Cox proportional hazard regressions (stratified by sex, age group, and year of index health care use) were performed to compare 10-year AD-free survival rates between the two cohorts, after adjusting for geographic region and the selected comorbidities. We also explored the relationship between primary SS and AD in different age groups. HR values along with 95% CIs were computed with a significance level of 0.05. All statistical analyses were conducted using the SAS statistical package (SAS System for Windows, V.9.2, SAS Institute Inc.) with the assistance of the Biostatistics Consulting Centre at the National Cheng Kung University Hospital.

Results

Our study identified 4463 patients in the primary SS cohort and 22,315 patients in the non-SS cohort. The analysis of the demographic data is presented in Table 1. Men accounted for 13.5% of each cohort. After matching for gender, age, and the index year, we found no significant differences in age or sex between the primary SS and non-SS patients. The primary SS cohort, however, had a higher prevalence of hyperlipidemia (p < 0.0001), hypertension (p < 0.0001), and coronary artery disease (p < 0.0001). There were no significant differences in the distribution of comorbidities between the groups DM (p = 0.26), HF (p = 0.26), AF (p = 0.43), and stroke (p = 0.43).
Table 1

Comparison of demographic characteristics and comorbidities of primary SS and non-SS patients

 

Patients with primary SS

(N = 4463)

Comparison patients

(N = 22,315)

 

Characteristic

N

%

N

%

p

Sex

    

1.0000

 Male

601

13.5

3005

13.5

 

 Female

3862

86.5

19,310

86.5

 

Age, year

    

1.0000

 < 36

403

9.03

2015

9.03

 

 36–50

1402

31.4

7010

31.4

 

 51–65

1599

35.8

7995

35.8

 

 > 65

1059

23.7

5295

23.7

 

Geographic region

    

< 0.0001

 Northern

1684

37.7

10,078

45.2

 

 Central

1430

32.0

4394

19.7

 

 Southern

1083

24.3

6699

30.0

 

 Eastern

266

5.96

1142

5.12

 

Comorbidities

     

 Diabetes

174

3.90

953

4.27

0.26

 Hyperlipidemia

137

3.07

424

1.90

< 0.0001

 Hypertension

441

9.88

1724

7.73

< 0.0001

 CAD

249

5.58

797

3.57

< 0.0001

 HF

52

1.17

219

0.98

0.26

 AF

30

0.67

128

0.57

0.43

 Stroke

146

3.27

687

3.08

0.50

CAD coronary artery disease, HF heart failure, AF atrial fibrillation

Table 2 shows the crude and adjusted HRs for AD during the 10-year follow-up period, after the year index between patients and controls. We found that, of the 26,778 sampled subjects, 20 patients experienced AD during the 10-year follow-up period, including 7 patients (0.16%) from the study cohort and 13 patients (0.06%) from the comparison cohort. The incidence of AD was 2.68-fold (95% CI, 1.07–6.73; p < 0.05) greater in the primary SS cohort than in the non-SS cohort, with an adjusted HR of 2.69 (95% CI, 1.07–6.76; p < 0.05). Figure 1 shows the disease-free survival curves using the Kaplan–Meier method.
Table 2

AD risk among sampled patients during the 10-year follow-up period from index health care utilization

 

Total

N = 26,778

Patients with primary SS

N = 4463

Comparison patients

N = 22,315

AD occurrence

N

%

N

%

N

%

Yes

20

0.08

7

0.16

13

0.06

No

26,758

99.9

4456

99.8

22,302

99.9

Crude HR (95% CI)

 

2.68 (1.07–6.73)*

1.00

Adjusted HR (95% CI)

 

2.69 (1.07–6.76)*

1.00

Hazard ratio was calculated by using the Cox proportional regression method during the 10-year follow-up period. Adjustments were made for demographic characteristics (age, sex, and the geographical region) and selected comorbidities in patients (diabetes, hyperlipidemia, hypertension, coronary artery disease, heart failure, atrial fibrillation, and stroke)

*p < 0.05

Fig. 1

AD-free survival rates of patients with primary SS and those in the comparison cohort in Taiwan, 2000 to 2010

Table 3 presents the prevalence HR and adjusted HR for AD between cohorts. The HR for primary SS patients older than 70 years was 3.69 (95% CI 1.28–10.6; p < 0.05), and an adjusted HR was 3.69 (95% CI 1.27–10.7; p < 0.05).
Table 3

Crude and adjusted hazard ratios of AD by different age groups among sampled patients during the 10-year follow-up from index health care utilization

 

Total

N = 26,778

Patients with primary SS

N = 4463

Comparison patients

N = 22,315

Age group

Event no.

%

Event no.

%

Event no.

%

< 69

6

0.03

1

0.03

5

0.03

 Crude HR (95% CI)

 

1.00 (0.12–8.56)

1.00

 Adjusted HR (95% CI)

 

0.95 (0.11–8.21)

1.00

≥ 70

14

0.34

6

0.88

8

0.23

 Crude HR (95% CI)

 

3.69 (1.28–10.6)*

1.00

 Adjusted HR (95% CI)

 

3.69 (1.27–10.7)*

1.00

Hazard ratio was calculated by using stratified Cox proportional regression (stratified on sex, age group, and the year of index health care use) during the 10-year follow-up period. Adjustments were made for patients’ select comorbidities (diabetes, hyperlipidemia, hypertension, coronary artery disease, heart failure, atrial fibrillation, and stroke)

*p < 0.05

Discussion

There have long been concerns regarding the relationship between SS and neuropsychiatric syndromes, including headache, cognitive dysfunction, mood disorder, and polyneuropathy [4]. Nevertheless, previous studies that have examined this relationship have some shortcomings, which include a small sample size, or a definitive diagnosis of AD [12, 13]. The prevalence of AD in primary SS has been unknown until now [18, 19]. To our knowledge, this is the first study that investigates the risk of AD among primary SS patients in Asia. Our retrospective, population-based cohort study, which was conducted with data obtained from Taiwan’s NHIRD, demonstrated that a primary SS diagnosis was independently associated with a 2.69-fold higher risk of subsequent AD, even after adjusting for region of residence and selected comorbidities. Compared to the non-SS cohort, crude and adjusted HRs for AD were highest in older patients (≧ 70 years old).

While cognitive symptoms are commonly experienced, very little is understood concerning the mechanisms of cognitive dysfunction in primary SS. There are several reasons why primary SS patients may have an increased risk of developing AD. Primary SS is a relatively common systemic autoimmune rheumatic disease, in which lymphocytic infiltration of salivary and lacrimal glands leads to immune-mediated secretory dysfunction [1]. In the past, diagnosis has depended on the presence of typical clinical features and/or parotid gland swelling together with focal lymphocytic infiltration demonstrated on biopsy of minor salivary glands and lips. However, serologic findings recently have been recognized to have diagnostic values. Serologic findings include autoantibodies against SS-A/Ro and SS-B/La, antinuclear antibodies, anti-salivary gland antibodies, and rheumatoid factor [20, 21]. The presence of anti-Ro (SS-A) antibodies defines a subset of patients with Sjögren’s syndrome who have systemic clinical manifestations including vasculitis, hematologic abnormalities, and serologic hyperreactivity [22]. Recently, another antibody was found and a pathophysiological role for circulating anti-muscarinic acetylcholine receptor (mAChR) autoantibodies in patients with primary SS was proposed. These autoantibodies recognized and activated mAChRs in both salivary and lacrimal glands [23]. There is a strong regulatory action of parasympathetic stimulation on the secretion of lacrimal and salivary glands [23]. Lacrimal and salivary gland mAChRs are coupled to various signaling pathways, and the production of nitric oxide is of particular interest, because it is involved in several pathologic processes, including SS, where increased levels of nitrites are found in the saliva [23] mAChRs that, acting as an “agonist-like agent,” resulted in a primary, organ-specific dysfunction. Possibly, in primary SS and secondary SS, direct mAChR antibody-mediated tissue damage might occur through nitric oxide generation and accumulation, with an adverse effect on the lacrimal glands. Immunologic generation of nitric oxide could have cytotoxic effects on the cell, through the production of free radicals [23]. This could have a special pathologic role, particularly in SS, where the increased release of inflammatory mediators could induce uncommonly high levels of nitric oxide [23]. It is known that anti-Ro/SSA and anti-La/SSB antibodies are directed against ribonucleoprotein complexes. Their localization is mainly cytoplasmic, and the increased expression of Ro52 in SS and SLE patients is probably implicated positively or negatively in the alteration of cellular immune responses and in the increased apoptosis observed in primary SS patients. Ro52 in primary SS can act as a negative regulator of interferon production, ubiquitination, and degradation of the transcription factors IRF-3, IRF-7, and IRF-8 inducing major alterations in cytokine expression and production [24]. The inflammatory response is associated with an increased risk of cognitive decline [25]. Cevimeline (M1 muscarinic agonist, AF102B) is a drug used in patients with SS to improve sicca symptoms, and it is recognized in innovative therapies for Alzheimer’s disease [26]. The M1 mAChR appears to be linked with two other major hallmarks of this disease β-amyloid (Aβ) and hyperphosphorylated τ proteins. Activation of M1 mAChR could alter beneficially Aβ and τ proteins and apolipoprotein E (ApoE), as well as some processes involving certain G-proteins and neurotrophins [26, 27]. Muscarinic agonists induce differentiation in PC12 cells stably transfected with M1 mAChR (PC12M1 cells), and these neurotrophic effects are synergistic with a variety of neurotrophins [26, 28]. Several studies showed that several neurotrophins (nerve growth factor [NGF], basic fibroblast growth factor [bFGF], and epidermal growth factor [EGF]) and muscarinic agonists induce neurite outgrowth via distinct intracellular pathways that cross-talk with each other. The agonist, via activation of M1 mAChR, restores learning and memory impairments with an excellent safety margin, mediate Aβ processing, and decrease τhyperphosphorylation, and thus may be useful in Alzheimer’s disease therapy [26]. In a recent animal study, a novel compound was reported, AF710B, a highly potent and selective allosteric M1 muscarinic and σ1 receptor agonist. AF710B exhibits an allosteric agonistic profile on the M1 muscarinic receptor; very low concentrations of AF710B significantly potentiated the binding and efficacy of carbachol on M1 receptors and their downstream effects (p-ERK1/2, p-CREB). The σ1 receptor (σ1R) is another potential target for drug development for AD, as it is considered to play a fundamental role in cognitive function. The compound could (i) mitigate cognitive impairments in the Morris water maze and (ii) decrease BACE1, SK3β activity, p25/CDK5, neuroinflammation, soluble and insoluble Aβ, Aβ, plaques and tau pathologies [29].

SS patients also were found to have significantly lower basal cortisol levels compared to healthy controls, which is thought to result from hypothalamic–pituitary–adrenal axis (HPA) deterioration [30, 31]. Le et al. [31] showed a significant correlation between cortical hypoperfusion and cognitive dysfunction. Another mechanism possibly linking SS to AD is the autoantibodies produced in SS, which may play a role in AD development. These autoantibodies can form an immune complex, and subsequently injure the endothelial walls of small blood vessels [19]. These studies further suggest that inflammation likely contributes to the pathogenesis of accelerating neurodegeneration among SS patients [19, 32].

We also found that, in comparison with patients without SS, primary SS patients were more likely to have hyperlipidemia, hypertension, and CAD. These factors also may explain the higher portion of AD in this cohort [9, 10, 11]. Our findings match the prevalence community-based reports that indicate that primary SS patients have higher cardiovascular risk factors at primary SS diagnosis. Akyel et al. [11] reported that myocardial function is disturbed in SS patients and there is significant atrial electromechanical delay. Our findings support their observation, in that we found a higher prevalence of CAD. Therefore, cardiovascular risk factors should be taken into account when managing such patients.

Autoimmune-induced dementia is an acute or sub-acute disorder that affects memory, cognition, and behavior. More importantly, autoimmune dementia is reversible and may be misdiagnosed as an irreversible neurodegenerative disorder [12, 13]. However, the true incidence rate of autoimmune dementia is unknown; therefore, it is difficult to assign correct ICD-9-CM codes to autoimmune dementia. A review by Rossor et al. [33] showed that young onset dementia had a higher prevalence of genetic or metabolic diseases. Most autoimmune dementia occurs in patients younger than 45 years, and AD is far more common in the geriatric population [34]. Therefore, different age groups were used to check and prevent misclassification errors. In the present study, most patients with primary SS and AD were more than 70 years old. The diagnosis of AD is highly suitable.

One major strength of our study was that it was based on a nationwide, population-based, case cohort study, which minimized the problems of insufficient power. Furthermore, the potential for selection biases was minimized by the comprehensive coverage of the NHI system and a large sample size.

Nevertheless, there are several limitations in our study. First, the diagnosis of primary SS and AD was made using the ICD-9 code from the database. NHIRD does not provide personal information, such as smoking preference, education level, and body mass index. Intelligence and education level also may have some effect on the occurrence of AD. These co-variables could not be adjusted in the analysis. Second, NHIRD provides limited information on clinical characteristics, such as disease severity, laboratory data, and imaging information. Therefore, it is hard to know the relationship between clinical severity and brain region involvement in primary SS and AD. Finally, the incidence rate of AD may be underestimated because inpatient claims data were used.

In conclusion, our nationwide cohort study found that patients with primary SS have a higher prevalence of AD than patients without primary SS. Although the evidence suggests that primary SS is a risk factor for AD, very little is known about the duration or clinical severity of primary SS or how it may contribute to AD. Therefore, further research in this area is necessary to answer such questions, and to examine whether proper management of primary SS may help prevent the occurrence of AD.

Notes

Acknowledgements

This study is based, in part, on data obtained from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health, Taiwan, and managed by the National Health Research Institutes. The interpretations and conclusions contained herein do not represent those of the Bureau of National Health Insurance, the Department of Health, or the National Health Research Institutes.

Contribution statement

Po-Chou Liliang, Cheng-Loong Liang, Kang Lu, and San-Nan Yang designed the research; Meng-Tsang Hsieh, Yi-Cheng Tai, and Kuo-Wei Wang analyzed the data; and Kuo-Wei Wang wrote the paper.

Compliance with ethical standards

This study was exempted from full review by the institutional review board.

Disclosures

None.

References

  1. 1.
    Rischmueller M, Tieu J, Lester S (2016) Primary Sjögren’s syndrome. Best Prac Res Clin Rheumatol 30(1):189–220CrossRefGoogle Scholar
  2. 2.
    Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, Brokstad K, Jonsson R, Jonsson MV (2011) Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren’s syndrome. Ann Rheum Dis 70(8):1363–1368.  https://doi.org/10.1136/ard.2010.144782 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lazarus MN, Robinson D, Mak V, Møller H, Isenberg DA (2006) Incidence of cancer in a cohort of patients with primary Sjögren’s syndrome. Rheumatology 45(8):1012–1015.  https://doi.org/10.1093/rheumatology/kei281 CrossRefPubMedGoogle Scholar
  4. 4.
    Harboe E, Tjensvoll AB, Maroni S, Goransson LG, Greve OJ, Beyer MK, Herigstad A, Kvaloy JT, Omdal R (2009) Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjögren syndrome: a comparative population-based study. Ann Rheum Dis 68(10):1541–1546.  https://doi.org/10.1136/ard.2008.098301 CrossRefPubMedGoogle Scholar
  5. 5.
    Yoshikawa K, Hatate J, Toratani N, Sugiura S, Shimizu Y, Takahash T, Ito T, Fukunaga R (2012) Prevalence of Sjögren’s syndrome with dementia in a memory clinic. J Neurol Sci 322(1-2):217–221.  https://doi.org/10.1016/j.jns.2012.07.060 CrossRefPubMedGoogle Scholar
  6. 6.
    Wang IK, Muo CH, Chang YC et al (2012) Risks, subtypes, and hospitalization costs of stroke among patients with systemic lupus erythematosus: a retrospective cohort study in Taiwan. J Rheumatol 39(8):1611–1618.  https://doi.org/10.3899/jrheum.111510 CrossRefPubMedGoogle Scholar
  7. 7.
    Zöller B, Li X, Sundquist J, Sundquist K (2012) Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol 12(1):41.  https://doi.org/10.1186/1471-2377-12-41 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Wallin K, Solomon A, Kåreholt I, Tuomilehto J, Soininen H, Kivipelto M (2012) Midlife rheumatoid arthritis increases the risk of cognitive impairment two decades later: a population-based study. J Alzheimers Dis 31(3):669–676.  https://doi.org/10.3233/JAD-2012-111736 PubMedGoogle Scholar
  9. 9.
    Ramos-Casals M, Brito-Zerón P, Sisó A, Vargas A, Ros E, Bove A, Belenguer R, Plaza J, Benavent J, Font J (2007) High prevalence of serum metabolic alterations in primary Sjögren’s syndrome: influence on clinical and immunological expression. J Rheumatol 34(4):754–761PubMedGoogle Scholar
  10. 10.
    Pérez-De-Lis M, Akasbi M, Sisó A, Diez-Cascon P, Brito-Zerón P, Diaz-Lagares C, Ortiz J, Perez-Alvarez R, Ramos-Casals M, Coca A (2010) Cardiovascular risk factors in primary Sjögren’s syndrome: a case-control study in 624 patients. Lupus 19(8):941–948.  https://doi.org/10.1177/0961203310367504 CrossRefPubMedGoogle Scholar
  11. 11.
    Akyel A, Tavil Y, Tufan A et al (2012) Atrial electromechanical delay and diastolic dysfunction in primary Sjögren syndrome. Clin Invest Med 35:E303CrossRefPubMedGoogle Scholar
  12. 12.
    Flanagan EP, McKeon A, Lennon VA, Boeve BF, Trenerry MR, Tan KM, Drubach DA, Josephs KA, Britton JW, Mandrekar JN, Lowe V, Parisi JE, Pittock SJ (2010) Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc 85(10):881–897.  https://doi.org/10.4065/mcp.2010.0326 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    McKeon A, Lennon VA, Pittock SJ (2010) Immunotherapy-responsive dementias and encephalopathies. Continuum (Minneap Minn) 16(2 Dementia):80–101.  https://doi.org/10.1212/01.CON.0000368213.63964.34 Google Scholar
  14. 14.
    Chi NF, Chien LN, HL K et al (2013) Alzheimer disease and risk of stroke: a population-based cohort study. Neurology 80(8):705–711.  https://doi.org/10.1212/WNL.0b013e31828250af CrossRefPubMedGoogle Scholar
  15. 15.
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH (2002) The European Study Group on Classification Criteria for Sjögren’s Syndrome Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558.  https://doi.org/10.1136/ard.61.6.554 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Chiang CJ, Yip PK, SC W et al (2007) Midlife risk factors for subtypes of dementia: a nested case-control study in Taiwan. Am J Geriatr Psychiatry 15(9):762–771.  https://doi.org/10.1097/JGP.0b013e318050c98f CrossRefPubMedGoogle Scholar
  17. 17.
    Wang HK, Lin SH, Sung PS, Wu MH, Hung KW, Wang LC, Huang CY, Lu K, Chen HJ, Tsai KJ (2012) Population based study on patients with traumatic brain injury suggests increased risk of dementia. J Neurol Neurosurg Psychiatry 83(11):1080–1085.  https://doi.org/10.1136/jnnp-2012-302633 CrossRefPubMedGoogle Scholar
  18. 18.
    Segal BM, Mueller BA, Zhu X, Prosser R, Pogatchnik B, Holker E, Carpenter AF, Lim KO (2010) Disruption of brain white matter microstructure in primary Sjögren's syndrome: evidence from diffusion tensor imaging. Rheumatology 49(8):1530–1539.  https://doi.org/10.1093/rheumatology/keq070 CrossRefPubMedGoogle Scholar
  19. 19.
    Kawashima N, Shindo R, Kohno M (1993) Primary Sjögren’s syndrome with subcortical dementia. Intern Med 32(7):561–564.  https://doi.org/10.2169/internalmedicine.32.561 CrossRefPubMedGoogle Scholar
  20. 20.
    Wharen M, Solomin L, Pettersson I, Isenberg D (1996) Autoantibodies repertoire to Ro/SSA and La/SSB antigen in patients with primary and secondary Sjo¨gren’s syndrome. J Autoimmun 9(4):537–544.  https://doi.org/10.1006/jaut.1996.0072 CrossRefGoogle Scholar
  21. 21.
    Atkinson JC, Royce LS, Wellner R (1995) Anti salivary antibodies in primary Sjogren’s syndrome. J Oral Pathol Med 24(5):206–212.  https://doi.org/10.1111/j.1600-0714.1995.tb01168.x CrossRefPubMedGoogle Scholar
  22. 22.
    Alexander EL, Arnett FC, Provost TT, Stevens MB (1983 Feb) Sjögren’s syndrome: association of anti-Ro (SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. Ann Intern Med 98(2):155–159.  https://doi.org/10.7326/0003-4819-98-2-155 CrossRefPubMedGoogle Scholar
  23. 23.
    Bacman S, Berra A, Sterin-Borda L, Borda E (2001) Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjo¨gren syndrome. Invest Ophthalmol Vis Sci 42:321–327PubMedGoogle Scholar
  24. 24.
    Reina S, Pisoni C, Arana R, Ganzinelli S, Borda E (2017) Role of M3 muscarinic acethylcholine Receptor Antibodies as a New Marker in Primary Sjögren Syndrome. Pharmacol Pharm 8:242–252CrossRefGoogle Scholar
  25. 25.
    Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, Launer L, Kuller L, Rubin S, Harris T (2003) Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 61(1):76–80.  https://doi.org/10.1212/01.WNL.0000073620.42047.D7 CrossRefPubMedGoogle Scholar
  26. 26.
    Fisher A, Brandeis R, Bar-Ner RHN, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z (2002) AF150(S) and AF267B M1 Muscarinic agonists as innovative therapies for Alzheimer’s disease. J Mol Neurosci 19(1-2):145–153.  https://doi.org/10.1007/s12031-002-0025-3 CrossRefPubMedGoogle Scholar
  27. 27.
    Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, Brandeis R (2003) M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease: implications in future therapy. J Mol Neurosci 20(3):349–356.  https://doi.org/10.1385/JMN:20:3:349 CrossRefPubMedGoogle Scholar
  28. 28.
    Gurwitz D, Haring R, Pinkas-Kramarski R, Stein R, Heldman E, Karton Y, Fisher A (1995) NGF-dependent neurotrophic-like effects of AF102B, an M1 muscarinic agonist, in PC12M1 cells. Neuroreport 6(3):485–488.  https://doi.org/10.1097/00001756-199502000-00020 CrossRefPubMedGoogle Scholar
  29. 29.
    Fisher A, Bezprozvanny I, Wu L, Ryskam DA, Natan NB-NN, Brandeis R, Elkon H, Nahum V, Gershonov E, LaFerla FM, Rodrigo ME (2016) AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer’s disease. Neurodegener Dis 16(1-2):95–110.  https://doi.org/10.1159/000440864 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Tzioufas AG, Tsonis J, Moutsopoulos HM (2008) Neuroendocrine dysfunction in Sjögren’s syndrome. Neuroimmunomodulation 15(1):37–45.  https://doi.org/10.1159/000135622 CrossRefPubMedGoogle Scholar
  31. 31.
    Johnson EO, Kostandi M, Moutsopoulos HM (2006) Hypothalamic-pituitary-adrenal axis function in Sjögren’s syndrome: mechanisms of neuroendocrine and immune system homeostasis. Ann N Y Acad Sci 1088(1):41–51.  https://doi.org/10.1196/annals.1366.018 CrossRefPubMedGoogle Scholar
  32. 32.
    Le Guern V, Belin C, Henegar C, Moroni C, Maillet D, Lacau C, Dumas JL, Vigneron N, Guillevin L (2010) Cognitive function and 99mTc-ECD brain SPECT are significantly correlated in patients with primary Sjögren’s syndrome: a case–control study. Ann Rheum Dis 69(01):132–137.  https://doi.org/10.1136/ard.2008.090811 CrossRefPubMedGoogle Scholar
  33. 33.
    Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362:329–344CrossRefPubMedGoogle Scholar
  34. 34.
    Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD (2010) The diagnosis of young-onset dementia. Lancet Neurol 9(8):793–806.  https://doi.org/10.1016/S1474-4422(10)70159-9 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2017

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Po-Chou Liliang
    • 1
  • Cheng-Loong Liang
    • 2
  • Kang Lu
    • 2
  • San-Nan Yang
    • 2
  • Meng-Tsang Hsieh
    • 3
  • Yi-Cheng Tai
    • 4
  • Kuo-Wei Wang
    • 1
  1. 1.Department of NeurosurgeryE-Da Cancer Hospital, I-Shou UniversityKaohsiungTaiwan
  2. 2.Department of NeurosurgeryE-Da Hospital, I-Shou UniversityKaohsiungTaiwan
  3. 3.School of Medicine for International StudentsI-Shou UniversityKaohsiungTaiwan
  4. 4.Department of NeurologyE-Da Hospital, I-Shou UniversityKaohsiungTaiwan

Personalised recommendations